Bright Green (BGXX) Competitors

Bright Green logo
$0.03 0.00 (-1.52%)
As of 02/13/2025 03:02 PM Eastern

BGXX vs. IRD, SNYR, RNXT, GRCE, IXHL, JATT, AKTX, INKT, LEXX, and CMMB

Should you be buying Bright Green stock or one of its competitors? The main competitors of Bright Green include Opus Genetics (IRD), Synergy CHC Corp. (Uplisting) (SNYR), RenovoRx (RNXT), Grace Therapeutics (GRCE), Incannex Healthcare (IXHL), JATT Acquisition (JATT), Akari Therapeutics (AKTX), MiNK Therapeutics (INKT), Lexaria Bioscience (LEXX), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

Bright Green vs.

Bright Green (NASDAQ:BGXX) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.

Opus Genetics has a consensus target price of $8.00, indicating a potential upside of 595.65%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Bright Green.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bright Green
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Opus Genetics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Opus Genetics has higher revenue and earnings than Bright Green. Opus Genetics is trading at a lower price-to-earnings ratio than Bright Green, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bright GreenN/AN/A-$13.13M-$0.06-0.54
Opus Genetics$19.05M1.91-$9.99M-$1.09-1.06

7.8% of Bright Green shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 62.5% of Bright Green shares are owned by insiders. Comparatively, 6.6% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bright Green has a net margin of 0.00% compared to Opus Genetics' net margin of -324.45%. Opus Genetics' return on equity of -63.65% beat Bright Green's return on equity.

Company Net Margins Return on Equity Return on Assets
Bright GreenN/A -88.37% -55.30%
Opus Genetics -324.45%-63.65%-56.94%

Bright Green has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.

Opus Genetics received 2 more outperform votes than Bright Green when rated by MarketBeat users.

CompanyUnderperformOutperform
Bright GreenN/AN/A
Opus GeneticsOutperform Votes
2
100.00%
Underperform Votes
No Votes

In the previous week, Opus Genetics had 2 more articles in the media than Bright Green. MarketBeat recorded 2 mentions for Opus Genetics and 0 mentions for Bright Green. Bright Green's average media sentiment score of 0.00 equaled Opus Genetics'average media sentiment score.

Company Overall Sentiment
Bright Green Neutral
Opus Genetics Neutral

Summary

Opus Genetics beats Bright Green on 10 of the 15 factors compared between the two stocks.

Get Bright Green News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGXX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGXX vs. The Competition

MetricBright GreenMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$6.21M$1.20B$5.81B$9.15B
Dividend YieldN/AN/A5.29%4.00%
P/E Ratio-0.5438.5126.0719.43
Price / SalesN/A5.79446.4071.49
Price / CashN/A10.8846.0938.87
Price / Book0.541.847.415.07
Net Income-$13.13M-$53.22M$3.19B$222.90M
7 Day PerformanceN/A0.15%0.92%1.23%
1 Month PerformanceN/A1.86%4.83%4.23%
1 Year PerformanceN/A-11.33%23.85%20.29%

Bright Green Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGXX
Bright Green
N/A$0.03
-1.5%
N/A-78.3%$6.21MN/A-0.542Gap Down
IRD
Opus Genetics
2.1212 of 5 stars
$1.08
-2.7%
$8.00
+640.7%
N/A$34.10M$19.05M-0.9914
SNYR
Synergy CHC Corp. (Uplisting)
N/A$3.87
+0.5%
$10.00
+158.4%
N/A$33.67MN/A0.0040
RNXT
RenovoRx
2.1007 of 5 stars
$1.37
+0.7%
$9.00
+556.9%
-34.4%$32.88MN/A-2.406News Coverage
GRCE
Grace Therapeutics
N/A$3.22
-2.4%
N/AN/A$32.65MN/A-3.19N/AEarnings Report
News Coverage
IXHL
Incannex Healthcare
0.363 of 5 stars
$1.84
+10.2%
N/A-48.1%$32.46M$10,000.00-1.323Short Interest ↑
Negative News
JATT
JATT Acquisition
N/A$1.88
+6.8%
N/A-64.1%$32.43MN/A0.003High Trading Volume
AKTX
Akari Therapeutics
N/A$1.20
+10.2%
N/A-54.8%$31.79MN/A0.009Gap Down
INKT
MiNK Therapeutics
2.6116 of 5 stars
$7.86
-14.2%
$65.00
+727.0%
-0.5%$31.13MN/A-2.0230
LEXX
Lexaria Bioscience
3.7686 of 5 stars
$1.77
flat
$9.50
+436.7%
-37.8%$31.06M$460,000.00-3.547Short Interest ↓
CMMB
Chemomab Therapeutics
2.8296 of 5 stars
$2.13
+4.4%
$7.50
+252.1%
+227.3%$30.59MN/A-2.1320Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:BGXX) was last updated on 2/14/2025 by MarketBeat.com Staff
From Our Partners